Dalton's GMP oligonucleotide facility ready to roll
Dalton Pharma Services, a privately-owned Canadian pharmaceutical services provider has completed the commissioning of its new oligonucleotide production suite.
Dalton Pharma Services, a privately-owned Canadian pharmaceutical services provider has completed the commissioning of its new oligonucleotide production suite.
The Toronto-based production suite is equipped with the latest technology for small to large-scale oligo production and purification.
Peter Pekos, Dalton's president and ceo, said: "Large-scale DNA and RNA oligonucleotide synthesis has now gained industry importance with proven therapeutic and diagnostic applications". He added, "With the expansion of our capabilities for the controlled synthesis of multigram quantities of oligonucleotides, Dalton will be able to play a greater role in both diagnostic oligonucleotide manufacturing and antisense therapeutics."
The facility has four AKTA OligoPilots each capable of producing oligos from 500 µmole to 50g scale of oligo per run. Purification is achieved using Waters preparative HPLC's, using either reverse phase or ion-exchange chromatographic techniques. Special controls, including environmental (HEPA filtered air) and manufacturing controls, have also been implemented.
